View Author
patient cancer study irinotecan pharmacokinetic phase grade treatment toxicity level plasma topotecan cycle sn -38 effect cisplatin inhibitor administration tumor -38 infusion concentration cpt -11 9- ac dose level phase i study table analysis activity neutropenia topoisomerase lactone oncol sample combination metabolite -11 diarrhea model phase i schedule result topoisomerase i inhibitors therapy range exposure trial agent response value death verweij j course clearance parameter verweij kinase dosing function intervention 9- ac lactone sn -38g group sequence camptothecin oncology blood growth 3 weeks inhibition chemotherapy phase ii study interaction dose levels sparreboom factor disease antitumor activity number cohort
10 Most Recent Publications
|
Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors
(Article)
Bendell, J.C. Rodon, J. Goldbrunner, M. Baselga, J. Burris, H.A. Jonge, M.J.A. de Verweij, J. Birle, D. Demanse, D. Buck, S.S. de Ru, Q.C. Peters, M. |
2012-01-20
|
|
Erlotinib dosing-to-rash: A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
(Article)
Mita, A. Papadopoulos, K. Hamilton, M. Iwata, K.K. Wacker, B. Witte, K. de Rowinsky, E.K. Jonge, M.J.A. de Schwartz, G. Verweij, J. Ricart, A. Chu, Q.S.C. Tolcher, A.W. Wood, L. McCarthy, S.W. |
2011-09-27
|
|
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
(Article)
Hamberg, P. Woo, M.M. Jonge, M.J.A. de Chen, L.C. Verweij, J. Porro, M.G. Zhao, L. Li, W. Biessen, D. van der Sharma, H.S. Hengelage, T. |
2011-06-27
|
|
Phase i safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
(Article)
Jonge, M.J.A. de Dumez, H. Kitzen, J.J.E.M. Beuselinck, B. Verweij, J. Courtney, R. Battista, A. Brega, N. Schöffski, P. |
2011-06-01
|
|
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: A prospective cross-over drug-drug interaction study
(Article)
Bol, J.M. van der Loos, W.J. Jonge, M.J.A. de Meerten, E. van Konings, I.R.H.M. Lam, M.H. Bruijn, P. de Wiemer, E.A.C. Verweij, J. Mathijssen, R.H.J. |
2011-04-01
|
|
Effects of methimazole on the elimination of irinotecan
(Article)
Bol, J.M. van der Visser, T.J. Loos, W.J. Jonge, M.J.A. de Wiemer, E.A.C. Aken, M.O. van Planting, A.S.Th. Schellens, J.H. Verweij, J. Mathijssen, R.H.J. |
2011-01-01
|
|
Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation
(Article)
Jonge, M.J.A. de Slingerland, M. Wiemer, E.A.C. Burger, H. Mathijssen, R.H.J. Kroep, J.R. Hollander, M.A.G. |
2010-11-01
|
|
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours
(Article)
Herpen, C.M.L. Eskens, F.A.L.M. Jonge, M.J.A. de Desar, I. Hooftman, L. Bone, E. Timmerbonte, J.N.H. Verweij, J. |
2010-10-26
|
|
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia
(Article)
Bol, J.M. van der Jonge, M.J.A. de Schaik, R.H.N. van Sparreboom, A. Fessem, M.A. van Geijn, F.E. van de Daele, P.L.A. van Verweij, J. Sleijfer, S. Mathijssen, R.H.J. |
2010-10-01
|
|
Phase i and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
(Article)
Konings, I.R.H.M. Jonge, M.J.A. de Burger, H. Gaast, A. van der Beijsterveldt, L.E.C. van Winkler, H. Verweij, J. Yuan, Z. Hellemans, P. Eskens, F.A.L.M. |
2010-09-28
|
